Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes

(2015) Yogen Saunthararajah et al.   JOURNAL OF CLINICAL INVESTIGATION

Epigenetic deregulation in myeloid malignancies

(2015) Kristen M. Meldi et al.   Translational Research

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

(2015)   Oncotarget

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

(2014) M. Bots et al.   BLOOD

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

(2014) Jean-Pierre Issa et al.   CANCER

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

(2014) Thomas Prebet et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone Acetylation Facilitates Rapid and Robust Memory CD8 T Cell Response through Differential Expression of Effector Molecules (Eomesodermin and Its Targets: Perforin and Granzyme B)

(2014) Y. Araki et al.   JOURNAL OF IMMUNOLOGY

PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia

(2014) G Tiberi et al.   LEUKEMIA

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

(2014) W Fiskus et al.   LEUKEMIA

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

(2014) P Tan et al.   Blood Cancer Journal

The anticancer effects of HDAC inhibitors require the immune system

(2014) Alison C West et al.   OncoImmunology

An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

(2013) A. C. West et al.   CANCER RESEARCH

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors

(2013) M New et al.   CELL DEATH AND DIFFERENTIATION

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

(2013) D J DeAngelo et al.   LEUKEMIA

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

(2013) Thomas Prebet et al.   LEUKEMIA RESEARCH

HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy

(2013) Byram W Bridle et al.   MOLECULAR THERAPY

PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential

(2012) W.-J. Shia et al.   BLOOD

Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

(2012) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages

(2012) X. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

(2011) T. Nguyen et al.   CLINICAL CANCER RESEARCH

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor

(2011) Wenjuan Yu et al.   LEUKEMIA RESEARCH

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors

(2011) J.-H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

(2011) A. J. Christiansen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone deacetylases as regulators of inflammation and immunity

(2011) Melanie R. Shakespear et al.   TRENDS IN IMMUNOLOGY

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound  -phenylethyl isothiocyanate

(2010) Y. Hu et al.   BLOOD

Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability

(2010) Srividya Bhaskara et al.   CANCER CELL

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

(2010) Thomas Prebet et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Nonhistone protein acetylation as cancer therapy targets

(2010) Brahma N Singh et al.   Expert Review of Anticancer Therapy

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

(2009) L. Ellis et al.   BLOOD

HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells

(2009) C. Urbich et al.   BLOOD

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

(2009) D. Mahalingam et al.   CLINICAL CANCER RESEARCH

Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor

(2009) Peter Gimsing   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A phase 2 study of vorinostat in acute myeloid leukemia

(2009) E. W. Schaefer et al.   HAEMATOLOGICA

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Targeting tumor angiogenesis with histone deacetylase inhibitors

(2008) Leigh Ellis et al.   CANCER LETTERS

Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

(2008) V. R. Fantin et al.   CANCER RESEARCH

Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

(2008) V. M. Klimek et al.   CLINICAL CANCER RESEARCH

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY